Bruker Announces First Quarter 2025 Preliminary Revenue

Rhea-AI Summary

Bruker (BRKR) has released preliminary revenue figures for Q1 2025, projecting revenue between $795 million to $800 million, exceeding both company outlook and consensus expectations. The company reported approximately 10% year-over-year revenue growth, with low-double digit percentage growth at constant exchange rates.

The Bruker Scientific Instrument (BSI) segment showed mid-single digit percentage organic revenue growth, while the BEST segment experienced a high-teens percentage organic revenue decline. Overall non-GAAP organic revenue growth was in the low-single digit percentages.

The company will release complete Q1 2025 financial results on May 7, 2025, before market opening, followed by an earnings conference call and webcast at 8:30 a.m. Eastern Daylight Time.

Positive

• Revenue of $795-800M exceeded company outlook and consensus
• 10% year-over-year revenue growth
• Low-double digit percentage growth at constant exchange rates
• Mid-single digit organic growth in BSI segment

Negative

• High-teens percentage organic revenue decline in BEST segment
• Overall non-GAAP organic revenue growth to low-single digits

Insights

Financial Analyst

Bruker's preliminary Q1 2025 revenue of $795-800 million represents a significant outperformance against both company guidance and market consensus. The ~10% year-over-year growth demonstrates strong momentum, particularly when considering the low-double digit constant exchange rate revenue expansion.

The segmental performance reveals a divergent story. The Bruker Scientific Instrument (BSI) segment delivered healthy mid-single digit organic growth, representing the core strength in the company's portfolio. This suggests robust demand for Bruker's analytical instruments, likely in key end markets such as biopharma and academic research.

However, the BEST segment's high-teens organic revenue decline raises concerns. This superconductor and magnet technology division appears to be facing substantial headwinds that could drag on overall company performance if not addressed.

What's particularly telling is management's decision to pre-announce these results approximately two weeks before their scheduled earnings call. This typically signals confidence in the numbers and a desire to promptly communicate positive developments to the market.

While the revenue picture is promising, investors should note that this preliminary announcement lacks crucial profitability metrics. The substantial revenue growth doesn't necessarily guarantee corresponding earnings improvements, as margins could be impacted by various factors including product mix, pricing pressures, or operational costs.

The company's ability to deliver this level of growth despite potential macroeconomic challenges demonstrates effective execution and possibly market share gains in key scientific instrument categories.

BILLERICA, Mass.--(BUSINESS WIRE)-- Bruker Corporation (Nasdaq: BRKR) today announced preliminary revenue for the first quarter ended March 31, 2025, in a range of $795 million to $800 million, comparing favorably to the Company’s earlier outlook and well ahead of consensus.

This estimated range implies reported revenue growth of approximately 10% year-over-year, with low-double digit percentage constant exchange rate revenue growth. Bruker estimates non-GAAP organic revenue growth in the first quarter to be in the low-single digit percentages, with mid-single digit percentage organic revenue growth in the Bruker Scientific Instrument (BSI) segment, and a high-teens percentage organic revenue decline in the BEST segment, net of intercompany eliminations.

Bruker expects to report its first quarter 2025 financial results before market opening on May 7, 2025.

First Quarter 2025 Earnings Conference Call and Webcast

Bruker presently plans to host a conference call and webcast on Wednesday, May 7, 2025, at 8:30 a.m. Eastern Daylight Time to discuss its first quarter financial results and business developments.

To listen to the webcast, investors can go to https://ir.bruker.com and click on the “Q1 2025 Earnings Webcast” hyperlink in the “Events & Presentations” section. A slide presentation will be referenced during the webcast and will be posted to the Company’s website shortly before the webcast begins.

Investors can also listen to the earnings webcast via telephone by dialing 1-888-437-2685 (U.S. toll free) or +1-412-317-6702 (international) and referencing “Bruker’s First Quarter 2025 Earnings Conference Call.”

Bruker is enabling investors to pre-register for the earnings conference call so that they can expedite their entry into the call and avoid the need to wait for a live operator. In order to pre-register for the call, investors can visit https://dpregister.com/sreg/10198987/fef65dcb43 and enter their contact information. Investors will then be issued a personalized phone number and PIN to dial into the live conference call. Individuals can pre-register any time prior to the start of the conference call on May 7.

A telephone replay of the conference call will be available by dialing 1-877-344-7529 (U.S. toll free) or +1-412-317-0088 (international) and entering replay access code: 1883665. The replay will be available beginning one hour after the end of the conference call through June 7, 2025.

About Bruker Corporation – Leader of the Post-Genomic Era (Nasdaq: BRKR)

Bruker is enabling scientists and engineers to make breakthrough post-genomic discoveries and develop new applications that improve the quality of human life. Bruker’s high performance scientific instruments and high value analytical and diagnostic solutions enable scientists to explore life and materials at molecular, cellular, and microscopic levels. In close cooperation with our customers, Bruker is enabling innovation, improved productivity, and customer success in post-genomic life science molecular and cell biology research, in applied and biopharma applications, in microscopy and nanoanalysis, as well as in industrial and cleantech research, and next-gen semiconductor metrology in support of AI. Bruker offers differentiated, high-value life science and diagnostics systems and solutions in preclinical imaging, clinical phenomics research, proteomics and multiomics, spatial and single-cell biology, functional structural and condensate biology, as well as in clinical microbiology and molecular diagnostics. For more information, please visit www.bruker.com.

Preliminary Financial Information

The anticipated results discussed in this press release are based on management’s preliminary, unaudited analysis of financial results for the quarter ended March 31, 2025. As of the date of this press release, Bruker has not completed its quarter end procedures for such period, and the Company’s independent registered accounting firm has not reviewed the preliminary financial data discussed in this press release. During the course of the Company’s quarter-end closing procedures and review process, the Company may identify items that would require it to make adjustments, which may be material to the information presented above. As a result, the estimates above constitute forward-looking information and are subject to risks and uncertainties, including possible adjustments to preliminary operating results.

Use of Non-GAAP Financial Measures

To supplement this preliminary consolidated financial information, which is prepared and presented in accordance with U.S. generally accepted accounting principles (GAAP), we also refer to organic revenue growth, a non-GAAP financial measure. We define the term organic revenue as GAAP revenue excluding the effect of changes in foreign currency translation rates and the effect of acquisitions and divestitures, and believe it is a useful measure to evaluate our continuing business.

The presentation of non-GAAP financial measures is not intended to be a substitute for, or superior to, the financial information prepared and presented in accordance with GAAP and may be different from non-GAAP financial measures used by other companies, and therefore, may not be comparable among companies. We believe this non-GAAP financial measure provides meaningful supplemental information regarding our performance, however we urge investors not to rely on any single financial measure to evaluate our business. Specifically, management believes that the non-GAAP measures mentioned above provide relevant and useful information which is widely used by analysts, investors and competitors in our industry, as well as by our management, in assessing both consolidated and business unit performance.

We use this and other non-GAAP financial measures to evaluate our period-over-period operating performance because our management believes this provides a more comparable measure of our continuing business by adjusting for certain items that are not reflective of the underlying performance of our business. This measure may also be useful to investors in evaluating the underlying operating performance of our business and forecasting future results. We regularly use non-GAAP financial measures internally to understand, manage, and evaluate our business results and make operating decisions. We also measure our employees and compensate them, in part, based on certain non-GAAP measures and use this information for our planning and forecasting activities.

Forward Looking Statements

Any statements contained in this press release which do not describe historical facts may constitute forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including statements regarding our preliminary first quarter financial results; and statements found under the “Use of Non-GAAP Financial Measures” section of this release. Any forward-looking statements contained herein are based on current expectations, but are subject to risks and uncertainties that could cause actual results to differ materially from those indicated, including, but not limited to, the completion of our quarter-end closing procedures and review process, the length and severity of any recession and the impact on global economic conditions, the impact of supply chain challenges, including inflationary pressures, the impact of geopolitical tensions and any sanctions, including any reduction in natural gas exports from Russia resulting from its ongoing conflict with Ukraine and resulting market disruptions, such as higher prices for and reduced availability of key metals used in our products, the conflict in Israel, Palestine and surrounding areas and the possible expansion of such conflicts and potential geopolitical consequences, the ongoing tensions between the United States and China, tariff and trade policy changes, and the increasing potential of conflict involving countries in Asia that are critical to our supply chain operations, such as Taiwan and China, continued volatility in the capital markets, the impact of increased interest rates, the integration and assumption of liabilities of businesses we have acquired or may acquire in the future, including our recent acquisitions of PhenomeX, ELITech, Chemspeed, and NanoString, our restructuring and cost-control initiatives, changing technologies, product development and market acceptance of our products, the cost and pricing of our products, manufacturing and outsourcing, competition, dependence on collaborative partners, key suppliers and third party distributors, capital spending and government funding policies, changes in governmental regulations, intellectual property rights, litigation, exposure to foreign currency fluctuations, the impact of foreign currency exchange rates, our ability to service our debt obligations and fund our anticipated cash needs, the effect of a concentrated ownership of our common stock, loss of key personnel, payment of future dividends and other risk factors discussed from time to time in our filings with the Securities and Exchange Commission, or SEC. These and other factors are identified and described in more detail in our filings with the SEC, including, without limitation, our annual report on Form 10-K for the year ended December 31, 2024, as may be updated by our quarterly reports on Form 10-Q. We expressly disclaim any intent or obligation to update these forward-looking statements other than as required by law.

View source version on businesswire.com: https://www.businesswire.com/news/home/20250411651079/en/

Joe Kostka

Director, Investor Relations

Bruker Corporation

T: +1 (978) 313-5800

E: Investor.Relations@bruker.com

Source: Bruker Corporation

FAQ

What is Bruker's (BRKR) projected revenue range for Q1 2025?

Bruker projects Q1 2025 revenue between $795 million to $800 million.

How much year-over-year revenue growth did BRKR report in Q1 2025?

BRKR reported approximately 10% year-over-year revenue growth.

What was the organic revenue performance of BRKR's BSI segment in Q1 2025?

The BSI segment showed mid-single digit percentage organic revenue growth.

How did BRKR's BEST segment perform in Q1 2025?

The BEST segment experienced a high-teens percentage organic revenue decline.

When will Bruker (BRKR) release its complete Q1 2025 financial results?

BRKR will release complete Q1 2025 results on May 7, 2025, before market opening.